Skip to main content

ESG approach

Public purpose, governance and environmental responsibility

NEUVIOR’s ESG approach is a framework for responsible company building. It is not an unaudited scorecard or a substitute for independently evidenced outcomes.

Explore sustainabilityUnderstand the evidence standard
Environmental | Baseline before impact claimsSocial | Public benefit without unsupported outcomesGovernance | Human accountability and evidence control

Environmental

Measure the footprint of real operations.

Environmental reporting should follow the actual company boundary and material activities. Feasibility work and future plans remain separate from achieved impact.

01

Operational boundary

Identify the activities and suppliers that are genuinely within scope.

02

Material data

Prioritise complete, reviewable data over a decorative score.

03

Transparent reporting

State the method, period and limitations beside any result.

Social purpose

Better medicines systems are the intended public benefit.

The ultimate beneficiary is the person who depends on a medicine, particularly someone underserved, excluded, confused or insufficiently supported.

NEUVIOR does not claim patient outcomes, lives affected or public sector value delivered without independent evidence.

01

Institutional action

Build tools intended to help responsible teams coordinate evidence and decisions.

Product intent
02

Understandable use

Keep patient education and clearer communication as long term public purpose domains.

Future intent
03

Outcome discipline

Report impact only where the causal basis and independent evidence support it.

Evidence boundary

Governance

The quality of the decision record matters.

Responsible growth requires clear authority, source provenance, conflict management, release control and a visible distinction between current fact and future intent.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Accountability

Name the person or body responsible for each material decision.

02

Evidence control

Retain the source, status and limitation behind public claims.

03

Progression gate

Continue, narrow, re architect or stop when evidence changes.

Classified public record

Review the complete research record

RESEARCH RECORD + CLAIM BOUNDARY

See the research record, and where the claim stops.

These publisher and partner pages preserve a dated record of historical NEUVIOR research activity. NEUVIOR does not restate confidential technical or funding details, and publication does not establish capability, performance or a live product.

  1. NEUVIOR Founder ReflectionsNEUVIOR analysis

    What feasibility research must prove

    Feasibility becomes useful when the question, constraints, evidence threshold and stop or continue decision are explicit before the work begins.

    See what feasibility research must prove
  2. Biorenewables Development CentrePartner announcement

    NEUVIOR research record

    A partner hosted record covering bounded NEUVIOR pharmaceutical materials research.

    Open the partner research record
  3. Yorkshire PostRelease derived reporting

    NEUVIOR research record

    A dated Yorkshire Post record covering bounded NEUVIOR pharmaceutical manufacturing waste research.

    See the project coverage
Explore related NEUVIOR analysis

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

Explore sustainabilitySpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What is NEUVIOR?

NEUVIOR is a pharmaceutical company registered in Scotland. It is building capabilities across medicines intelligence, governed technology and longer term development. PHARMORIS is its immediate product priority.

02What does NEUVIOR build today?

NEUVIOR is developing PHARMORIS, a human-governed medicines operations system in controlled, non-production development. It is intended to connect evidence, decisions, accountable work and value review. No independent TRL, deployment, customer adoption or clinical validation is claimed.

03What is PHARMORIS by NEUVIOR?

PHARMORIS is a configurable medicines operations system under controlled development. It is designed to help authorised teams progress medicine opportunities from evidence linked to its source, through an owned ActionCase, a human decision, delivery and review.

04Who founded NEUVIOR?

Varun Sharma is the Founder, CEO and CTO of NEUVIOR and leads the company and PHARMORIS product architecture.

05Where does NEUVIOR have a presence?

NEUVIOR works across Glasgow, London and Mumbai. Glasgow is the company origin and registered Scottish base. London supports commercial activity led by the founder. Mumbai supports market engagement in India and relationships across the pharmaceutical sector. These are different forms of presence. They do not imply three registered offices or regulated facilities.